870961-95-8Relevant articles and documents
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2
Wissner, Allan,Floyd, M. Brawner,Johnson, Bernard D.,Fraser, Heidi,Ingalls, Charles,Nittoli, Thomas,Dushin, Russell G.,Discafani, Carolyn,Nilakantan, Ramaswamy,Marini, Joseph,Ravi, Malini,Cheung, Kinwang,Tan, Xingzhi,Musto, Sylvia,Annable, Tami,Siegel, Marshall M.,Loganzo, Frank
, p. 7560 - 7581 (2007/10/03)
A series of 2-(quinazolin-4-ylamino)-[1,4] benzoquinone derivatives that function as potent covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2 (VEGFR-2) has been prepared by eerie ammonium nitrate oxidation of substituted (2,5- dimethoxyphenyl)(6,7-disubstituted-quinazolin-4-yl)amines and by displacement of the chlorine atom of substituted 2-chloro-5-(6,7-disubstituted-quinazolin-4- ylamino)[1,4]benzoquinones with various amines, anilines, phenols, and alcohols. Enzyme studies were conducted in the absence and presence of glutathione and plasma. Several of the compounds inhibit VEGF-stimulated autophosphorylation in intact cells. Kinetic experiments were performed to study the reactivity of selected inhibitors toward glutathione. Reactivities correlated with LUMO energies calculated as averages of those of individual conformers weighted by the Boltzmann distribution. These results and molecular modeling were used to rationalize the biological observations. The compounds behave as non-ATP-competitive inhibitors. Unequivocal evidence, from mass spectral studies, indicates that these inhibitors form a covalent interaction with Cys-1045. One member of this series displays antitumor activity in an in vivo model.
